NEW YORK (GenomeWeb News) – NanoString Technologies this week appointed Wayne Cowens as its chief medical officer. Cowens will drive the development of the company's pipeline of molecular diagnostics for cancer, the firm said.
He joins NanoString from Genomic Health, where since 2004 he served in a series of senior medical positions, including vice president of clinical oncology, and led the development of the company's Oncotype DX breast cancer recurrence test. Cowens previously held senior product development and clinical affairs positions at Chiron and Ribozyme Pharmaceuticals, and he worked at Idec Pharmaceuticals, Scios, and Ligand Pharmaceuticals.
Roche said this week in a financial report that it will nominate Nestle CEO Paul Bulcke, Deutsche Lufthansa CEO and Chairman Christoph Franz, and Royal Dutch Schell CEO Peter Voser for election to its board of directors at its 2011 annual general meeting. The company also will propose that terms for board members will be reduced from three to two years. Roche said in December 2010 that Walter Frey and Wolfgang Ruttenstorfer will not stand for re-election to its board.
Erik Holmlin has been named president, CEO, and director of BioNanomatrix, where he will succeed Edward Erickson. As GenomeWeb Daily News reported this week, Holmlin formerly was president and CEO at GenVault, which has been acquired by IntegenX.
Flourotechnics said this week that James Walker will leave his posts as managing director and CEO, but he will retain his position as an executive director. He will supervise the transition of the firm's German manufacturing business and its ongoing Australian business, and will remain the primary contact point for the operations of Flourotechnics Limited.
Hologic has appointed Mark Myslinski to SVP and GM, Diagnostics. In the role, he will oversee the company's cytology and molecular diagnostics products in its Diagnostics Group. Myslinksi formerly was CEO and president of RedPath Integrated Pathology. He also has served as VP and GM at Veridex, and he was a member of the board of Ortho Clinical Diagnostics.
BGI Americas has made changes to its management team. CEO Julia Dan and President Paul Tu are no longer with the company. It has not yet hired replacements.
BGI Americas also has named Joyce Peng to be marketing director. Previously, Peng was the strategic alliance growth manager at Illumina, and she was product manager of proteomics at Rosetta Biosoftware.
Trans-Hit Biomarkers announced that René Paulussen is its new chief operating officer. Paulussen brings to the Montreal, Quebec-based firm 20 years of experience in scientific research and business management. Before joining Trans-Hit Biomarkers, Paulussen was COO of Genizon Biosciences from 2002.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.